The institutional review board at each participating center approved this study, and documented informed consent was obtained from all enrolled patients. Details regarding the chemoresponse assay employed in this study (ChemoFx;

Precision Therapeutics Inc, Pittsburgh, selleck compound PA) have been described elsewhere.13 Briefly, the inhibition of tumor growth was measured at different concentrations of each therapy. The survival fraction of tumor cells at each concentration was calculated as compared to a control (no drug). The summation of survival fraction values over 7 concentrations was computed as the drug response score, which represents the area under the dose-response curve (AUC). A smaller AUC score indicates greater sensitivity to the therapy. Chemoresponse

is classified into 1 of 3 categories according to the AUC score: sensitive, intermediate sensitive (IS), or resistant. The classification criterion was defined based on the distribution of AUC scores among an external population of patients with primary EOC. Specifically, the distributions of AUC scores for carboplatin and paclitaxel were established based on referent specimens. Scores ranked at the 25th and UMI-77 clinical trial 75th percentiles were obtained. A tumor with an AUC score <25th rank was classified as sensitive, between 25th-75th rank as IS, and >75th rank as resistant. The primary endpoint of this study was PFS, calculated from the start of chemotherapy administration until the date of first documented disease recurrence, death, or most recent follow-up. Commonly utilized patient prognostic information was also collected, including: age, Eastern Cooperative Oncology Group performance status, histology, tumor grade, stage, debulking status, and type of chemotherapy administered. The physician(s) at each institution reported all clinical information, which was quality controlled according to a comprehensive

monitoring plan. Disease unless progression was determined by clinical evidence, radiological examination, and/or cancer antigen 125. Optimal debulking was defined as residual tumor of ≤1 cm in maximal dimension at the end of surgery and was reported by enrolling physicians. PFS based on assay response was estimated using the Kaplan-Meier method, and the log rank test was used to compare the differences among sensitive, IS, and resistant patients. Since the primary objective of the current study was to identify platinum-resistant patients, sensitive and IS groups were combined for further analyses. The association of the assay and PFS was also assessed using Cox regression model adjusted for clinical covariates (age, performance status [1-3 vs 0], histology [high-grade serous vs non-high-grade serous], and stage/debulking status [III-suboptimal/IV vs III-optimal]).